In summary, this report provides the first comprehensive analysis of post‐transplant outcomes of patients with TP53 mutant AML, because previous studies have mainly focused on the influence of TP53 mutations, among other genetic factors, in patients with MDS.8, 9. Here, TP53 is linked to myelodysplastic syndrome.